(Total Views: 597)
Posted On: 05/21/2020 1:09:55 PM
Post# of 153940
Re: Coocooburra #34918
There's a lot of material to unpack!
I do think we have our answer as to how BP *knows* who is on leronlimab. They have an CCR5 occupancy assay to ensure leronlimab is doing its magic. That is how he likely knows when leronlimab is at play and when it is not.
His argument is so well stated... We are missing the diagnostics to explain the science behind the outcomes in many of these covid treatments. With leronlimab we have detailed analysis that matches clinical outcomes.
Another interesting point that I noted was that IL6 is normal while RANTES is elevated, and that RANTES is the target. An IL6 inhibitor is simply attacking one of the byproducts.
I do think we have our answer as to how BP *knows* who is on leronlimab. They have an CCR5 occupancy assay to ensure leronlimab is doing its magic. That is how he likely knows when leronlimab is at play and when it is not.
His argument is so well stated... We are missing the diagnostics to explain the science behind the outcomes in many of these covid treatments. With leronlimab we have detailed analysis that matches clinical outcomes.
Another interesting point that I noted was that IL6 is normal while RANTES is elevated, and that RANTES is the target. An IL6 inhibitor is simply attacking one of the byproducts.
(5)
(0)
